Editing Transient ischemic attack (section)

=== Antiplatelet medications ===
The [[Antiplatelet drug|antiplatelet medications]], [[aspirin]] and [[clopidogrel]], are both recommended for secondary prevention of stroke after high-risk TIAs.<ref>{{Cite web |date=2020-02-13 |title=Preventing Stroke in Patients with Atrial Fibrillation - Evidence Update for Clinicians {{!}} PCORI |url=https://www.pcori.org/evidence-updates/preventing-stroke-in-patients-atrial-fibrillation-evidence-update-for-clinicians |access-date=2024-09-09 |website=www.pcori.org |language=en}}</ref><ref name=":2">{{cite journal | vauthors = Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA | display-authors = 6 | title = Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association | journal = Stroke | volume = 45 | issue = 7 | pages = 2160–2236 | date = July 2014 | pmid = 24788967 | doi = 10.1161/STR.0000000000000024 | author19 = American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease | doi-access = free }}</ref><ref name=Hap2018>{{cite journal | vauthors = Hao Q, Tampi M, O'Donnell M, Foroutan F, Siemieniuk RA, Guyatt G | title = Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis | journal = BMJ | volume = 363 | pages = k5108 | date = December 2018 | pmid = 30563866 | pmc = 6298178 | doi = 10.1136/bmj.k5108 }}</ref> The clopidogrel can generally be stopped after 10 to 21 days.<ref name=Hap2018/> An exception is TIAs due to blood clots originating from the heart, in which case [[anticoagulant]]s are generally recommended.<ref name=":2" /> After TIA or minor stroke, aspirin therapy has been shown to reduce the short-term risk of recurrent stroke by 60–70%, and the long-term risk of stroke by 13%.<ref>{{cite journal | vauthors = Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z | title = Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials | journal = Lancet | volume = 388 | issue = 10042 | pages = 365–375 | date = July 2016 | pmid = 27209146 | pmc = 5321490 | doi = 10.1016/S0140-6736(16)30468-8 }}</ref>

The typical therapy may include aspirin alone, a combination of aspirin plus extended-release [[dipyridamole]], or [[clopidogrel]] alone.<ref name=":2" /> Clopidogrel and aspirin have similar efficacies and side effect profiles. Clopidogrel is more expensive and has a slightly decreased risk of GI bleed.<ref name=":2" /> Another antiplatelet, [[ticlopidine]], is rarely used due to increased side effects.<ref name=":2" />